ImPact Biotech receives FDA Orphan Drug Designation for Padeliporfin VTP in Pancreatic Cancer

ImPact Biotech announced the FDA granted Orphan Drug Designation to Padeliporfin Vascular Targeted Photodynamic therapy (VTP) for the treatment of patients with locally advanced pancreatic cancer.